Cohort Study | Dolutegravir in pregnancy as compared with current HIV regimens.
1 Sep, 2022 | 11:55h | UTCDolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States – New England Journal of Medicine (link to abstract – $ for full-text)
Related:
RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.
WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations
RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.
Commentary on Twitter
In this study involving 1257 pregnancies among persons treated for HIV-1 infection during pregnancy, dolutegravir was better at suppressing viral loads than other regimens, without evident safety concerns. https://t.co/CnShoao995 pic.twitter.com/Qne24I1482
— NEJM (@NEJM) August 31, 2022